TY - JOUR T1 - Mycophenolate Mofetil in Refractory Cutaneous Lupus Erythematosus: No Definitive Evidence JF - The Journal of Rheumatology JO - J Rheumatol SP - 1766 LP - 1766 DO - 10.3899/jrheum.160437 VL - 43 IS - 9 AU - CLAUDE BACHMEYER AU - SIMON GALMICHE AU - ANTOINE FAYAND AU - ALEXANDRE DEGACHI AU - SOPHIE GEORGIN-LAVIALLE Y1 - 2016/09/01 UR - http://www.jrheum.org/content/43/9/1766.1.abstract N2 - To the Editor:We read with great interest the article by Tselios, et al on mycophenolate mofetil (MMF) in nonrenal manifestations of systemic lupus erythematosus (SLE)1. The study suggested that this treatment is an efficacious alternative in refractory to standard-of-care of nonrenal manifestations of SLE in the long term1. However, some data are lacking to change our clinical practice. For instance, with regard to cutaneous lupus erythematosus (CLE) lesions, an improvement was observed at 6 and 12 months in 25.9% and 40.7% of patients without renal involvement, respectively, and at 6 and 12 months in 33.3% and 53.3% of patients with renal involvement, respectively1. Such a result is very interesting in our daily practice because of conflicting data in the literature, as indicated by the authors. However, we have a few comments on this article about … Address correspondence to Dr. C. Bachmeyer, Service de Médecine Interne, Hôpital Tenon (AP-HP), 4 rue de la Chine, 75020 Paris, France. E-mail: claude.bachmeyer{at}tnn.aphp.fr ER -